The most recent estimate of the Exubera (inhaled insulin) rollout has been delayed again, this time until January 2007, according to a Pfizer report. The company cites manufacturing issues in the scale-up process as the cause of the delay. This news follows speculation by some that the product may not become the blockbuster as originally touted, including a report in Business Week that cited Exubera's clunky, large-sized inhaler and required periodic lung function tests as reasons for doubt.
To see more Hot off the Press news articles, click here.
